6 Meridian’s Regeneron Pharmaceuticals REGN Stock Holding History

6 Meridian’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-409	Closed	-$228K	–	477
2021 Q2	$228K	Buy	+409	New	+$207K	0.02%	296

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

6 Meridian's REGN Position: Q3 2021 in Review

6 Meridian sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 409 shares — an estimated $228K sold.

6 Meridian first reported a position in REGN in Q2 2021 and held it in 1 quarter. The position peaked at $228K in Q2 2021. 1,019 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

6 Meridian reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
6 Meridian sold 409 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $228K.
6 Meridian first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 1 quarter.
6 Meridian's Regeneron Pharmaceuticals position peaked at $228K in Q2 2021.
1,019 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on 6 Meridian's 13F filing for Q3 2021, filed 3 Nov 2021.